CALGB 10403 in Latin America: A Single-Center Study With Extended Follow-Up (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-1176; Location: LEVEL 3, HALL B3; "CALGB 10403 is feasible and yields outcomes comparable to the original trial in a Latin American center with extended follow-up.MRD and leukocyte count are strong independent prognostic factors. Blinatumomab consolidation was independently associated with improved survival; mature outcomes of this unselected cohort are anticipated in the coming years."
Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Fausto Alfredo Rios-Olais MD; Manuel Alejandro Cruz-Martinez MD; Juan Luis Ontiveros-Austria MD; Roberta Demichelis-Gomez MD
|